Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted and appeared in  Type 1 DiabetesIssue 613

Autoantigen Treatment Benefits Type 1's

Autoantigen treatment of new-onset type 1 diabetes was unsuccessful in preserving pancreatic beta-cell function overall, but the treatment did appear to help in certain prespecified patient subgroups....


According to Johnny Ludvigsson, MD, PhD, from Linköping University in Linköping, Sweden, and colleagues, patients given the autoantigen glutamic acid decarboxylase (GAD) had similar declines in insulin secretion as measured by stimulated C-peptide levels as did patients given placebo, with an estimated treatment ratio of 1.16 (95% CI 0.97 to 1.40, P=0.10). Males, however, had a 41% greater preservation of C-peptide, with an estimated treatment ratio of 1.41 (95% CI 1.09 to 1.83, P=0.01), the researchers reported.

Dr. Ludvigsson stated that, "Instead of saying that this study shows that we should abandon GAD and autoantigen treatment, I think the result supports the concept that GAD can be used to preserve residual insulin secretion, although we need to learn more about dosing, intervals, and which groups of patients will have the best effect." 

The use of autoantigens in type 1 diabetes is based on the hypothesis that induction of immune tolerance could stop the autoimmune process of pancreatic beta-cell destruction.

In a previous study that included 70 patients, Ludvigsson's group found that treatment with the 65-kD isoform of GAD preserved fasting C-peptide levels for more than two years and stimulated levels for 15 months, indicating residual insulin secretion. So they conducted a nine-country randomized trial that enrolled 327 patients ages 10 to 20 within three months of being diagnosed with type 1 diabetes.

Patients were randomized to receive subcutaneous injections of 20 µg GAD65 formulated with alum at baseline, one month, three months, and nine months; injections at one and three months plus two placebo injections; or four injections of placebo.

Patients in the two active treatment groups showed increases in levels of GAD autoantibodies by three months that were significantly higher than in the placebo group (P<0.001).

As with the primary endpoint of stimulated C-peptide levels at 15 months, there were no significant differences compared with placebo on various secondary endpoints, including change in fasting C-peptide (P=0.07), change in daily insulin dose (P=0.57), and change in glycated hemoglobin (P=0.86).

However, the investigators also performed multiple exploratory analyses to identify potential treatment effects in patient subgroups, and found differences not only according to sex, but also for insulin requirements, degree of maturation, and location.

Among patients whose baseline insulin dose was 0.398 to 0.605 IU/kg per day, the estimated treatment ratio was 1.33 (95% CI 1 to 1.78, P=0.05). For those whose baseline Tanner stage was 2 or 3, the ratio in the four-dose group was 1.52 (P=0.04), and the ratio for the more southern countries such as Italy and Spain was 1.36 (P=0.04), the researchers reported.

Adverse events were similar in the treatment and placebo groups, and there were no cases of stiff person syndrome, a neurologic disorder associated with high GAD65 levels.

In discussing why the results of this study contradicted those seen in the earlier trial, the investigators explained that there may have been differences in the study population or in participating clinicians' traditional treatment approaches.

Seasonal factors also may have contributed, because patients who began treatment in the spring seemed to fare better, and an outbreak of influenza with widespread immunization also may have influenced the results. In addition, the treatment groups included more patients ages 10 and 11, while the placebo group included greater numbers of 16-to-20 year olds.

Ludvigsson added that, "Nobody would expect to use one single drug in one single type of dosing for treatment of all types of cancer in all ages, so why would we believe that all type 1 diabetes in all ages, genders, and countries should be treated with just one design?"

"Much as treatments for childhood cancer and immunotherapy of allergy have developed in a stepwise, gradual manner through the combination of existing therapies, treatment for type 1 diabetes will most likely be based on the knowledge gained from this and other studies, as well as future studies, of single agents and combination therapies for both intervention and prevention," he and his co-investigators concluded.

Practice Pearls:
  • This multicenter study found no effect of the autoantigen glutamic acid decarboxylase on insulin secretion at 15 months in type 1 diabetics enrolled within three months of diagnosis.
  • Insulin secretion does appear better preserved in certain subgroups, such as males, younger children, those living in more southern climates, and those taking lower baseline doses of insulin.

Ludvigsson J, et al "GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus" New Engl J Med 2012; 366: 433-442.



Bookmark and Share | Print | Category | Home

This article originally posted 15 February, 2012 and appeared in  Type 1 DiabetesIssue 613

Past five issues: Issue 796 | Diabetes Clinical Mastery Series Issue 255 | Issue 795 | SGLT-2 Inhibitors Special Edition August 2015 | Diabetes Clinical Mastery Series Issue 254 |

2015 Most Popular Articles:

Coffee Consumption Proves Potential in Reducing Type 2 Diabetes Risk
Posted August 07, 2015
Impaired Glucose Uptake in the Brain May Increase Alzheimer's Disease Risk
Posted August 07, 2015
First Non-Surgical Weight Loss Procedure for Mild-to-Moderate Obesity
Posted August 07, 2015
GLP-1 Agonist Semaglutide Completes Phase III Trial with Positive Results
Posted August 07, 2015
Two New Possible Methods for Diagnosing and Monitoring Diabetes
Posted August 07, 2015
Impact of Switching Insulin Glargine to Insulin Detemir in T2 Patients
Posted August 14, 2015
Diabetes Combination Drug LixiLan Meets Main Target in Late Stage Trial
Posted August 07, 2015
SIgnificant Weight Gain Associated with Laparoscopic Sleeve Gastrectomy
Posted August 14, 2015
Ketoacidosis Not as Great as Thought in Diabetes Patients Taking Invokana
Posted August 13, 2015
A Telltale Sign of Type 2 Diabetes
Posted August 07, 2015

Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Richard K. Bernstein, MD | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
What percentage of your patients have reached goal for A1c, BP and cholesterol?

CME/CE of the Week
Presented by CardioCareLive
Category: Cardiology